Search Results

Talis Biomedical Corporation announced it has initiated a process to explore strategic alternatives with the goal of maximizing shareholder value.

Talis Biomedical Corporation today announced that it has appointed Dr. Andrew A. Lukowiak as president and chief scientific officer, effective August 1, 2023.

Talis Biomedical Corporation, a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, reported financial results for the second quarter ended June 30, 2023, and provided a business update.

Talis Biomedical Corporation today announced that it received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated July 20, 2023, that the Company has regained compliance with the minimum bid price requirement of at least $1.00 per share.

Talis Biomedical Corporation announced a business update and reported financial results for the first quarter ended March 31, 2023.

Talis Biomedical Corporation (Nasdaq: TLIS) today announced new data supporting the development of its planned CT/NG/TV and vaginal infection panels.

Talis Biomedical Corporation today announced that it will effect a 1-for-15 reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 per share (the “Reverse Stock Split”), effective at 5:00 p.m. Eastern time on July 5, 2023 (the “Effective Time”).

Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will provide a business update and financial results on Thursday, May 11, 2023, after market close.